Exploratory Neuroimaging Study to Evaluate the Effect on Brain Activity of SPN-810 for Impulsive Aggression (IA) in Patients With Attention-Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 22 Nov 2019 Status changed from recruiting to discontinued.
- 07 Jun 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
- 07 Jun 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Mar 2020.